How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,203 results for

Genital Herpes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Genital Herpes: Gynaecological Aspects

Genital Herpes: Gynaecological Aspects No. 207-Genital Herpes: Gynaecological Aspects - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 39, Issue 7, Pages e105–e111 No. 207-Genital Herpes: Gynaecological Aspects x Deborah Money , MD (Principal Author) Vancouver, BC x Marc Steben , MD (Principal Author) Montréal, QC No. 207, April 2008 DOI: To view the full text, please login as a subscribed user or . Click to view (...) the full text on ScienceDirect. Abstract Objective The purpose of this guideline is to provide recommendations to gynaecology health care providers on optimal management of genital herpes. Outcomes More effective prevention of complications and transmission of genital herpes. Evidence Medline was searched for articles published in French and English related to genital herpes and gynaecology. Additional articles were identified through the references of these articles. All study types and recommendation

2017 Society of Obstetricians and Gynaecologists of Canada

3. Interventions for men and women with their first episode of genital herpes. (PubMed)

Interventions for men and women with their first episode of genital herpes. Genital herpes is incurable, and is caused by the herpes simplex virus (HSV). First-episode genital herpes is the first clinical presentation of herpes that a person experiences. Current treatment is based around viral suppression in order to decrease the length and severity of the episode.To determine the effectiveness and safety of the different existing treatments for first-episode genital herpes on the duration (...) ), and the Alternative Medicines Specialised Register (from inception to April 2016). We handsearched a number of relevant journals, searched reference lists of all included studies, databases of ongoing trials, and other Internet databases.We included randomised controlled trials (RCTs) on participants with first-episode genital herpes. We excluded vaccination trials, and trials in which the primary objective assessed a complication of HSV infection.All studies written in English were independently assessed

Full Text available with Trip Pro

2016 Cochrane

4. WHO guidelines for the treatment of Genital Herpes Simplex Virus

WHO guidelines for the treatment of Genital Herpes Simplex Virus WHO GUIDELINES FOR THE Treatment of Genital Herpes Simplex VirusWHO GUIDELINES FOR THE Treatment of Genital Herpes Simplex Virus WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of genital herpes simplex virus I.World Health Organization. ISBN 978 92 4 154987 5 Subject headings are available from WHO institutional repository © World Health Organization 2016 All rights reserved. Publications of the World (...) epidemiology and burden 5 Why new guidelines for the prevention, treatment and management of STIs? 5 Approach to the revision of STI guidelines 6 References 8 WHO guidelines for the treatment of genital herpes simplex virus 9 1. Introduction 9 1.1 Epidemiology, burden and clinical considerations 9 Clinical presentation 9 Laboratory diagnosis 10 1.2 Rationale for new recommendations 10 1.3 Objectives 10 1.4 Target audience 10 1.5 Structure of the guidelines 11 2. Methods 12 2.1 Guideline Development Group

2016 World Health Organisation Guidelines

5. Genital Herpes Infection: Serologic Screening

Genital Herpes Infection: Serologic Screening Final Update Summary: Genital Herpes Infection: Serologic Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Genital Herpes Infection: Serologic Screening Release Date: November 2016 Recommendation Summary Population Recommendation Grade Asymptomatic adolescents and adults, including those who are pregnant The USPSTF recommends (...) against routine serologic screening for genital herpes simplex virus (HSV) infection in asymptomatic adolescents and adults, including those who are pregnant. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . ( ) Related Information for Consumers There is no related information for consumers. Related Information for Health Professionals There is no related information for health professionals. Supporting Documents ( ) ( ) Clinical Summary Clinical

2016 U.S. Preventive Services Task Force

6. Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials. (PubMed)

Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials. Although herpes simplex viruses (HSV) are a major target for vaccine development no vaccine is currently licensed.A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig model of genital herpes. Three doses (...) of intramuscular (IM) vaccine were provided followed by intravaginal challenge with HSV-2 at either 3 weeks or six months after the last vaccination.Both VC2 and gD2 vaccines reduced acute genital disease. VC2 was somewhat more effective in reducing acute vaginal replication, the amount of virus in neural tissue, subsequent recurrent disease and recurrent virus shedding following challenge at 3 weeks post vaccination. Both vaccines continued to provide protection at 6 months after vaccination

Full Text available with Trip Pro

2019 PLoS ONE

7. Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. (PubMed)

Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. We tested whether genital herpes simplex virus (HSV) shedding is an appropriate surrogate outcome for the clinical outcome of genital herpes lesions in studies of HSV-2 antiviral interventions.We analyzed prospective data from natural history studies and clinical trials of antiviral agents for HSV-2 in which (...) is an appropriate surrogate outcome for genital herpes lesions because it is in the causal pathway to recurrences.

Full Text available with Trip Pro

2018 Journal of Infectious Diseases

8. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. (PubMed)

Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Genital herpes is caused by herpes simplex virus 1 (HSV-1) or 2 (HSV-2). Some infected people experience outbreaks of genital herpes, typically, characterized by vesicular and erosive localized painful genital lesions.To compare the effectiveness and safety of three oral antiviral drugs (acyclovir, famciclovir and valacyclovir) prescribed to suppress genital herpes outbreaks in non (...) trials including patients with recurrent genital herpes caused by HSV, whatever the type (HSV-1, HSV-2, or undetermined), with at least four recurrences per year (trials concerning human immunodeficiency virus (HIV)-positive patients or pregnant women were not eligible) and comparing suppressive oral antiviral treatment with oral acyclovir, famciclovir, and valacyclovir versus placebo or another suppressive oral antiviral treatment.Two review authors independently selected eligible trials

Full Text available with Trip Pro

2014 Cochrane

9. How well do antivirals shorten genital herpes pain duration?

How well do antivirals shorten genital herpes pain duration? How well do antivirals shorten genital herpes pain duration? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics How well do antivirals shorten genital herpes pain duration? View/ Open Date 2015-03 Contributor Format Metadata Abstract Q: How well do antivirals (...) shorten genital herpes pain duration? Evidence-based answer: Oral and intravenous (IV) acyclovir each shorten the duration of pain for a first primary outbreak of herpes by about 50%; topical acyclovir shortens it by about 25% (strength of recommendation [SOR]: B, small randomized controlled trials [RCTs] with some methodological flaws). Oral valacyclovir and famcyclovir are equivalent to oral acyclovir. Adding topical acyclovir to oral acyclovir doesn’t produce additional benefit (SOR: B, RCTs

2015 Clinical Inquiries

10. Management of Genital Herpes in Pregnancy

Management of Genital Herpes in Pregnancy Management of Genital Herpes in Pregnancy October 20142 Management of Genital Herpes in Pregnancy Foley E, Clarke E, Beckett VA, Harrison S, Pillai A, FitzGerald M, Owen P , Low-Beer N, Patel R. Guideline date: October 2014 Date of review: by 2018 Guideline development group: Elizabeth Foley MB BS BSc FRCP FRCOG (lead author), Consultant in Genitourinary and HIV Medicine, Solent NHS Trust Emily Clarke BSc BM MSc MRCP (UK), ST3 Genitourinary Medicine (...) , Solent NHS Trust Virginia Beckett MB BS BSc FRCOG (lead author on behalf of RCOG), Consultant Obstetrician and Gynaecologist, Bradford Teaching Hospitals NHS Foundation Trust, Honorary Senior Lecturer, University of Bradford Sam Harrison MRCOG, ST6 Obstetrics and Gynaecology, Bradford Teaching Hospitals NHS Foundation Trust Anil Pillai MRCP, Consultant Neonatologist, Bradford Teaching Hospitals NHS Foundation Trust Mark FitzGerald FRCP, Lead Editor, BASHH guideline on Management of Genital Herpes

2014 Royal College of Obstetricians and Gynaecologists

11. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model (PubMed)

A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model An estimated 417 million people worldwide ages 15 to 49 are infected with herpes simplex virus type 2 (HSV-2), the most common cause of genital ulcer disease. Some individuals experience frequent recurrences of genital lesions, while others only have subclinical infection, yet all risk transmitting infection to their intimate partners. A vaccine was developed (...) that prevents shingles, which is a recurrent infection caused by varicella-zoster virus (VZV), a closely related member of the Herpesviridae family. The success of the VZV vaccine has stimulated renewed interest in a therapeutic vaccine for genital herpes. We have been evaluating a trivalent subunit antigen vaccine for prevention of genital herpes. Here, we assess the trivalent vaccine as immunotherapy in guinea pigs that were previously infected intravaginally with HSV-2. The trivalent vaccine contains HSV

Full Text available with Trip Pro

2017 Human vaccines & immunotherapeutics

12. Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study. (PubMed)

Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study. We performed a randomized double-blind controlled trial to compare the efficacy and safety of multistrain probiotic and acyclovir in women patients with recurrent genital herpes simplex virus type 2 (HSV-2) infections. Eighty-one patients enrolled in the study were being treated with multistrain Lactobacillus brevis one vaginal capsule (...) , and no side effect of L. brevis are valuable properties of probiotic therapy compared with acyclovir. Therefore, we concluded that multistrain L. brevis could play an important role in suppression of recurrent genital herpes simplex virus infection.

2019 Probiotics and antimicrobial proteins

13. Unusual manifestation of disseminated herpes simplex virus type 2 infection associated with pharyngotonsilitis, esophagitis, and hemophagocytic lymphohisitocytosis without genital involvement. (PubMed)

Unusual manifestation of disseminated herpes simplex virus type 2 infection associated with pharyngotonsilitis, esophagitis, and hemophagocytic lymphohisitocytosis without genital involvement. Herpes simplex virus (HSV) has various presentations, depending on the patient's immune status, age, and the route of transmission. In adults, HSV type 1 is found predominantly in the oral area, and HSV type 2 (HSV-2) is commonly found in the genital area. HSV-2 infection without genital lesions (...) is uncommon. Herein we report a unique case of pharyngotonsillitis as an initial manifestation of disseminated HSV-2 infection without genital involvement.A 46-year-old male was admitted to our hospital with a 1-week history of fever and sore throat. His past medical history included hypereosinophilic syndrome diagnosed at age 45 years. Physical examination revealed throat congestion, bilaterally enlarged tonsils with exudates, tender cervical lymphadenopathy in the left posterior triangle, and mild

Full Text available with Trip Pro

2019 BMC Infectious Diseases

14. Genital Herpes

Genital Herpes Rotation Prep | NEJM Resident 360 Social Login Email Login Log in via Email Create Your Account We will not share your email with anyone. Password must be at least 8 characters. Show or Hide the password you are typing. Request to Join has invited you to join this group Your browser does not support video tags Welcome! NEJM Resident 360 helps you prepare for your next rotation quickly and efficiently, provides support for coping with the pressures of resident life, and equips you

2016 Now@NEJM

15. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes. (PubMed)

Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes. Amenamevir is the international non-proprietary name for ASP2151 synthesized by Astellas Pharma, Inc. It is a structurally novel class of helicase-primase inhibitor and demonstrated more potency in vitro anti-viral activity with low cytotoxicity against varicella-zoster virus (VZV), herpes simplex virus type 1 (HSV-1), and herpes simplex (...) virus type 2 (HSV-2) than acyclovir (ACV). Phase II randomized trial assessed the safety and efficacy of ASP2151 for episodic therapy of recurrent genital herpes was conducted. Participants self-initiated with ASP2151 (100, 200, or 400 mg daily for 3 days), ASP2151 (1,200 mg as a single dose), placebo for 3 days, or Valacyclovir (500 mg twice daily for 3 days). We present a first population pharmacokinetic (PPK) modeling analysis of Amenamevir for genital herpes patients. The final model retained

2018 Clinical pharmacology in drug development

16. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. (PubMed)

Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. Genital herpes is a prevalent sexually transmitted infection in the United States, occurring in almost 1 in 6 persons aged 14 to 49 years. Infection is caused by 2 subtypes of the herpes simplex virus (HSV), HSV-1 and HSV-2. Antiviral medications may provide symptomatic relief from outbreaks but do not cure HSV infection. Neonatal herpes infection, while uncommon, can result (...) in substantial morbidity and mortality.To update the 2005 US Preventive Services Task Force (USPSTF) recommendation on screening for genital herpes.The USPSTF reviewed the evidence on the accuracy, benefits, and harms of serologic screening for HSV-2 infection in asymptomatic persons, including those who are pregnant, as well as the effectiveness and harms of preventive medications and behavioral counseling interventions to reduce future symptomatic episodes and transmission to others.Based on the natural

Full Text available with Trip Pro

2016 JAMA

17. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Genital herpes simplex virus (HSV) infection is a prevalent sexually transmitted infection. Vertical transmission of HSV can lead to fetal morbidity and mortality.To assess the evidence on serologic screening and preventive interventions for genital HSV infection in asymptomatic adults and adolescents to support the US Preventive Services Task Force for an updated (...) recommendation statement.MEDLINE, Cochrane Library, EMBASE, and trial registries through March 31, 2016. Surveillance for new evidence in targeted publications was conducted through October 31, 2016.English-language randomized clinical trials (RCTs) comparing screening with no screening in persons without past or current symptoms of genital herpes; studies evaluating accuracy and harms of serologic screening tests for HSV-2; RCTs assessing preventive interventions in asymptomatic persons seropositive for HSV

Full Text available with Trip Pro

2016 JAMA

18. Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. (PubMed)

Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. Here we present genomic and in vitro analyses of temporally separated episodes of herpes simplex virus type 1 (HSV-1) shedding by an HSV-1-seropositive and human immunodeficiency virus (HIV)/HSV-2-seronegative individual who has frequent recurrences of genital HSV-1. Using oligonucleotide enrichment, we compared viral genomes from uncultured swab specimens collected on different days and from (...) distinct genital sites. We found that viral genomes from 7 swab specimens and 3 cultured specimens collected over a 4-month period from the same individual were 98.5% identical. We observed a >2-fold difference in the number of minority variants between swab specimens from lesions, swab specimens from nonlesion sites, and cultured specimens. This virus appeared distinct in its phylogenetic relationship to other strains, and it contained novel coding variations in 21 viral proteins. This included

Full Text available with Trip Pro

2018 Journal of Infectious Diseases

19. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice (PubMed)

STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice In recent years, there has been an increasing interest in immunomodulatory therapy as a means to treat various conditions, including infectious diseases. For instance, Toll-like receptor (TLR) agonists have been evaluated for treatment of genital herpes. However, although the TLR7 agonist imiquimod was shown to have antiviral activity in individual patients, no significant effects (...) expression. In contrast to TLRs, STING is expressed broadly, including in epithelial cells. Here we report that natural and non-natural STING agonists strongly induce type I IFNs in human cells and in mice in vivo, without stimulating significant inflammatory gene expression. Systemic treatment with 2'3'-cGAMP reduced genital herpes simplex virus (HSV) 2 replication and improved the clinical outcome of infection. More importantly, local application of CDNs at the genital epithelial surface gave rise

Full Text available with Trip Pro

2018 PLoS pathogens

20. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs (PubMed)

Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) subunit antigen is included in many preclinical candidate vaccines. The rationale for including gD2 is to produce antibodies that block crucial gD2 epitopes involved in virus entry and cell-to-cell spread. HSV-2 gD2 was the only antigen in the Herpevac (...) Trial for Women that protected against HSV-1 genital infection but not HSV-2. In that trial, a correlation was detected between gD2 ELISA titers and protection against HSV-1, supporting the importance of antibodies. A possible explanation for the lack of protection against HSV-2 was that HSV-2 neutralization titers were low, four-fold lower than to HSV-1. Here, we evaluated neutralization titers and epitope-specific antibody responses to crucial gD2 epitopes involved in virus entry and cell-to-cell

Full Text available with Trip Pro

2018 PLoS pathogens

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>